NeuroFrontiers is produced in collaboration with the American Academy of Neurology and explores new research, diagnosis and treatment in all areas of neurological disease. This series also addresses the most relevant clinical topics, trends, news and advances pertaining to all areas of the practice of Neurology. Series Produced In Cooperation With
Date | Title & Description | Contributors |
---|---|---|
2024-10-22 |
Reducing the ALS Diagnostic Delay: The Impacts of a Rapid Access Clinic Guest: Kelly Gwathmey, MD ALS can take up to a year to diagnose, but researchers are hard at work trying to find ways to minimize diagnostic delays and errors. One such solution is the Rapid Access ALS Clinic, where patients were diagnosed an... |
|
2024-10-18 |
Evaluating the Impacts of TD: The Role of Patient-Reported Outcomes Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Stacy Finkbeiner, PhD Guest: Bill Cote To gain insights into how tardive dyskinesia (TD) can impact the physical, psychological, social, and professional lives of patients, the IMPACT-TD... |
|
2024-10-18 |
Assessing TD’s Impact Using Clinician-Reported Measures: A Poster from Psych Congress Elevate Host: Ashley Baker, MSN, PMHNP Guest: Stacy Finkbeiner, PhD The IMPACT-TD Registry is an ongoing, real-world observational study that aims to better understand the multidimensional impacts of tardive dyskinesia (TD) on patients’ lives. To... |
|
2024-10-09 |
Breaking Barriers: Effective Screening for Tardive Dyskinesia Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrew J. Cutler, MD Guest: Michelle Scargle, MD Tardive dyskinesia is quite common as up to 20 percent of patients may develop this hyperkinetic movement disorder. But despite its preva... |
|
2024-10-09 |
Evaluating the Effects of Tardive Dyskinesia with the IMPACT-TD Scale Host: Ashley Baker, MSN, PMHNP Guest: Richard Jackson, MD The IMPACT-TD scale enables us to evaluate the effects of tardive dyskinesia across four key domains: psychological/psychiatric, social, physical, and vocational/educational/recrea... |
|
2024-09-11 |
Continuum of Care: Managing DMD in Pediatric and Adult Patients Guest: John F. Brandsema, MD As patients with Duchenne muscular dystrophy (DMD) age, their treatment regimens, considerations, and goals change. That’s why Dr. John Brandsema is here to talk about how we can best treat and support patients wi... |
|
2024-09-11 |
Comprehensive Care: Navigating Neurobehavioral Issues in DMD Patients Guest: John F. Brandsema, MD Between 60 and 70 percent of patients with Duchenne muscular dystrophy (DMD) also have a diagnosable neurobehavioral phenotype like autism, ADHD, and anxiety. Here to talk about these common neurobehavioral issues... |
|
2024-09-10 |
Advances in DMD Care: Evaluating a Gene Therapy’s Efficacy and Safety Host: Charles Turck, PharmD, BCPS, BCCCP Guest: John F. Brandsema, MD The gene therapy delandistrogene moxeparvovec was recently approved for patients with Duchenne muscular dystrophy (DMD) who are at least 4 years old. This expanded appr... |
|
2024-09-04 |
Researching the Overlap: Hepatic Encephalopathy and Dementia in Focus Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jasmohan Bajaj, MD Around 50 percent of people with cirrhosis have hepatic encephalopathy, which means some kind of brain dysfunction. As these patients age, it gets more and more difficult ... |
|
2024-08-29 |
The Impact of a cholesterol-lowering medication on Alzheimer’s Disease Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Dr. Robert J. Shmookler Reis, PhD Guest: Dr. Srinivas Ayyadevara, PhD Numerous factors could predispose patients to the progression of mild cognitive impairment or dementia and Alzheimer... |